Semaglutide vs Liraglutide: evidence, status and structure
A side-by-side look at Semaglutide and Liraglutide, using the data on each VALREXA profile. Neither comparison is a recommendation.
Key differences
- Both sit at the same evidence level: Approved use.
- Both have the same U.S. status category: FDA-approved.
| Semaglutide | Liraglutide | |
| Research class | Metabolic Research | Metabolic Research |
| Human evidence | Approved use | Approved use |
| U.S. status | FDA-approved (Ozempic, Rybelsus, Wegovy) | FDA-approved (Victoza, Saxenda) |
| 2026 compounding decision | — | — |
| Amino acids | 31 (modified) | 31 (modified) |
| Molecular weight | ~4,113.6 Da | ~3,751.2 Da |
| Formula | C₁₈₇H₂₉₁N₄₅O₅₉ | C₁₇₂H₂₆₅N₄₃O₅₁ |
| Sequence | — | — |
| Research period | 2017 | 2010 |
| Safety summary | FDA-approved as Ozempic, Rybelsus and Wegovy (injection and tablet) for specific indications. Common side effects are gastrointestinal, and labels include a boxed warning about thyroid C-cell tumors seen in rodents. Products sold online as “research” semaglutide are not the approved drug. | FDA-approved; labels include a boxed warning about thyroid C-cell tumors seen in rodents. |
How they differ
Both are GLP-1 receptor agonists made by Novo Nordisk, and both are FDA-approved. The main practical difference is duration: liraglutide is injected once daily, while semaglutide was engineered for once-weekly injection (and a daily tablet form). Structural changes, including a fatty-acid side chain that binds albumin, give semaglutide its longer half-life.
What each one is
Semaglutide: GLP-1 receptor agonist peptide, modified to last about a week in the body. Molecular weight, sequence, research history, human evidence and regulatory status.
Liraglutide: Once-daily GLP-1 receptor agonist with a fatty-acid chain. Molecular weight, sequence, research history, human evidence and regulatory status.
Educational reference only. Nothing here is medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error.